Engineering Inclusivity in Modern Medicine
Our mission is to eliminate the invisible barriers to care by creating a world where no patient is left behind due to genetic or metabolic incompatibilities.
The Era of "One-Size-Fits-All" is Over.
For decades, blockbuster drugs have been formulated for the average metabolism, forcing millions to endure severe adverse reactions or forgo treatment entirely.
Excipy was founded to challenge this accepted compromise. We believe that with modern computational power, therapeutics must be reformulated to adapt to the patient, rather than forcing the patient to adapt to the therapeutic.
Led by Science. Driven by Data.
Bridging the frontier of artificial intelligence and translational medicine. Our team unites researchers from top-tier institutions to de-risk drug formulation and accelerate the next generation of precision therapeutics.
Kian Tayebi
Founder & CEO
Kian bridges the critical gap between algorithmic potential and biological reality. Anchored by a specialized background in Cell Biology and Genetics from Boston University and ongoing advanced research at NYU, Kian leverages his deep domain expertise to drive Excipy’s pipeline and translate computational models into viable, patient-centric formulations.
Alireza Majd
Translational Medicine & Bioinformatics
Alireza anchors Excipy’s clinical methodology, ensuring our computational models translate into viable, real-world medical applications. Holding both an MD and an MPH, and currently serving as a Postdoctoral Scholar at UCSF, he brings nearly a decade of specialized expertise in bioinformatics and pharmacology. His rigorous medical background bridges the gap between algorithmic prediction and clinical reality.
Ruthvika Kosuri
Generative AI & Computational Workflows
Ruthvika drives the engineering and deployment of Excipy’s generative AI platforms. With an advanced background in Computer Science and Bioinformatics from UNC-Chapel Hill, she brings highly specialized experience from the UNC Eshelman School of Pharmacy. Her expertise in packaging scalable machine learning models (including LLMs and molecular dynamics) accelerates our computational drug evaluation and formulation pipelines.
Parsa Hejabi
Deep Learning & AI Architecture
Parsa leads the development of Excipy’s proprietary machine learning infrastructure. An AI researcher and PhD candidate in Computer Science at USC, his expertise lies in Natural Language Processing and Graph Convolutional Neural Networks (GCNNs). At Excipy, Parsa builds the complex predictive models and automated data pipelines required to accurately map molecular structures and drug formulations.
Proudly Backed by Bridgewest Ventures
Excipy is supported by Bridgewest Ventures, a premier deep-tech and life sciences venture capital firm. This strategic partnership provides Excipy not only with robust capital backing but also with access to a global ecosystem of regulatory experts, clinical strategists, and industry veterans to accelerate our pathway to market.
Join the Formulation Revolution
We are actively expanding our team of computational biologists, data scientists, and pharmaceutical strategists. Follow us on LinkedIn for information on open roles.